Here we describe the validation of Digistain Prognostic Score (DPS), developed by incorporating DI with clinicopathological features, to predict 5- and 10-year recurrence-free survival (RFS), recurrence and overall survival (OS) in a well-characterized cohort of patients with early HR-positive HER2-negative breast cancer who had received systemic adjuvant endocrine therapy, but no chemotherapy. Here, ERBB2 is linked to breast carcinoma.